Physician profile
Christopher Corriveau
NPI 1811479728
$2,037.74
in general payments reported to CMS, 2019-2025
19 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2023: $615 · 2024: $811 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $345.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $299.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $219.44 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $164.32 | 2023-2024 | |
| Novo Nordisk INC | $161.00 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $155.88 | 2024-2025 | |
| Boston Scientific Corporation | $120.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.55 | 2023-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $80.95 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $76.98 | 2023-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $73.52 | 2023-2024 | Xarelto |
| Dexcom, INC. | $68.20 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $50.64 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $44.57 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $24.91 | 2024 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $17.13 | 2025 | Qutenza |
| Paratek Pharmaceuticals, INC. | $16.05 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.50 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.74 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Corriveau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.